Pristinamycin IIA: Difference between revisions
CSV import |
CSV import |
||
| Line 24: | Line 24: | ||
{{pharmacology-stub}} | {{pharmacology-stub}} | ||
<gallery> | |||
File:Streptogramin_A.svg|Streptogramin A structure | |||
File:Virginiamycin_M1_Biosynthesis_3.tif|Virginiamycin M1 Biosynthesis | |||
</gallery> | |||
Latest revision as of 00:56, 18 February 2025
Pristinamycin IIA is a macrolide antibiotic that is part of the pristinamycin family. It is produced by the bacterium Streptomyces pristinaespiralis. Pristinamycin IIA is used in the treatment of Gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
Chemistry[edit]
Pristinamycin IIA is a macrocyclic lactone with a 16-membered ring. It is a glycoside that contains a sugar moiety, L-ristosamine, attached to the macrolactone ring. The macrolactone ring contains several functional groups, including a ketone, an ester, and an alkene.
Mechanism of action[edit]
Pristinamycin IIA inhibits protein synthesis in bacteria by binding to the 50S ribosomal subunit. This prevents the formation of a functional 70S initiation complex, which is essential for the translational process. As a result, the growth of the bacteria is inhibited.
Clinical use[edit]
Pristinamycin IIA is used in the treatment of infections caused by Gram-positive bacteria, including MRSA. It is particularly effective against Staphylococcus aureus and Streptococcus pyogenes. Pristinamycin IIA is usually administered orally.
Side effects[edit]
The most common side effects of pristinamycin IIA include nausea, vomiting, diarrhea, and rash. In rare cases, it can cause hepatotoxicity and allergic reactions.
See also[edit]
-
Streptogramin A structure
-
Virginiamycin M1 Biosynthesis
